Table 1.
Baseline characteristics in patients with small-cell lung cancer
Patients (n=74) | |
---|---|
Age (years) | 61 (55–69) |
| |
Sex | |
Female | 32 (43%) |
Male | 42 (57%) |
| |
ECOG performance score | |
0 | 21 (28%) |
1 | 50 (68%) |
2 | 3 (4%) |
| |
Response to first-line treatment | |
Sensitive* | 39 (53%) |
Resistant† | 23 (31%) |
Refractory‡ | 7 (9%) |
Not assessable | 5 (7%) |
| |
Treatment-free interval before second-line treatment (months) | 4·1 (1·8–7·9) |
| |
Previous lines of treatment | |
One | 39 (53%) |
Two | 35 (47%) |
| |
History of CNS metastases | 21 (28%) |
| |
Previous treatments | |
Platinum and etoposide | 71 (96%) |
Platinum and other drug | 5 (7%) |
Platinum, etoposide, and other drug | 7 (9%) |
Topotecan | 8 (11%) |
Temozolomide | 10 (14%) |
ABT-888 | 8 (11%) |
Radiation | 61 (82%) |
Other | 16 (22%) |
| |
Tumour DLL3 expression§ | |
≥1% | 42/48 (88%) |
≥50% | 32/48 (67%) |
Data are median (IQR) or number of patients (%). ECOG=Eastern Cooperative Group.
Defined as a best response of stable disease or better to first-line treatment, and a treatment-free interval between first-line and second-line treatment of 90 days or longer.
Defined as a best response of stable disease or better to first-line treatment, and a treatment-free interval between first-line and second-line treatment of less than 90 days.
Defined as a best response of progressive disease to first-line treatment.
Percentage of tumour cells staining positive for DLL3; calculated only in patients with available archived tumour tissue.